Heart disease test maker Singulex files for $86M IPO

Alameda diagnostic test developer Singulex Inc. filed for an $86.25 million initial public offering Friday, promising a test to measure signs of heart disease at previously undetectable levels. Using the Jumpstart Our Business Startups, or JOBS, Act to qualify as an "emerging growth company," 15-year-old Singulex said in a filing with the Securities and Exchange Commission that its technology helps to earlier detect and monitor biomarkers of heart attacks, heart failure, stroke and other heart diseases.

Gilead four-in-one HIV drug passes another test

Gilead Sciences Inc.’s four-in-one quad pill for AIDS patients was as effective as its own three-in-one drug Atripla, but perhaps just as importantly didn’t increase cholesterol levels to the same levels.
The once-a-day pill from Foster City-based Gilead (NASDAQ: GILD) combines emtricitabine and tenofovir, which make up the Gilead therapy Truvada, and elvitegravir, which Gilead licensed from Japan Tobacco Inc., and a Gilead-developed booster called cobicistat.

Gilead HIV booster passes Phase III test

An experimental HIV therapy booster from Gilead Sciences Inc. — a key part of Gilead’s experimental four-in-one, once-a-day Quad pill — met the goal of a Phase III trial, the company said Monday.
The booster, named cobicistat, showed in the 96-week study that it was at least on par with ritonvair, or Norvir, from Abbott Laboratories (NYSE: ABT), Gilead (NASDAQ: GILD) said.